Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia

Clicks: 597
ID: 115672
2018
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
In acute myeloid leukemia (AML), MLL (KMT2A) rearrangements are among the most frequent chromosomal abnormalities; however, knowledge of the genetic landscape of MLL-rearranged AML is limited. In this study, we performed whole-exome sequencing (n = 9) and targeted sequencing (n …
Reference Key
h2018bloodrecurrent Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Matsuo H;Yoshida K;Fukumura K;Nakatani K;Noguchi Y;Takasaki S;Noura M;Shiozawa Y;Shiraishi Y;Chiba K;Tanaka H;Okada A;Nannya Y;Takeda J;Ueno H;Shiba N;Yamato G;Handa H;Ono Y;Hiramoto N;Ishikawa T;Usuki K;Ishiyama K;Miyawaki S;Itonaga H;Miyazaki Y;Kawamura M;Yamaguchi H;Kiyokawa N;Tomizawa D;Taga T;Tawa A;Hayashi Y;Mano H;Miyano S;Kamikubo Y;Ogawa S;Adachi S;;
Journal blood advances
Year 2018
DOI
DOI not found
URL
https://www.pubmed.gov/30381403/
Keywords
leukemia National Center for Biotechnology Information NCBI NLM MEDLINE RNA humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't female male adolescent Child Infant Recurrence newborn preschool mutation survival rate myeloid acute / mortality small interfering / metabolism acute / metabolism pmid:30381403 pmc6234363 doi:10.1182/bloodadvances.2018019398 hidemasa matsuo kenichi yoshida souichi adachi cyclin d / genetics cyclin d3 / antagonists & inhibitors cyclin d3 / genetics* cyclin d3 / metabolism dna copy number variations g1 phase cell cycle checkpoints / drug effects gene rearrangement histone-lysine n-methyltransferase / genetics* acute / pathology* myeloid-lymphoid leukemia protein / genetics* protein kinase inhibitors / pharmacology rna interference

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.